Hematolojik maligniteli hastalarda serum kolesterol ve trigliserid değerlerinin araştırılması

Abstract

Bu çalışmada yeni tam konmuş ve spesifik tedavi almamış değişik hematolojik maligniteli olgularda serum total kolesterol ve trigliserid düzeyleri ölçülerek, hiperkolesterolemi ve hipertrigliseridemi sıklığı araştırıldı. 31 'i kronik fenfosilik lösemi (KLL), 40'ı Non-Hodgkin Lenfoma (NHL), 31 'i Hodgkin Lenfoma (HL), 29'u kronik mielositik lösemi (KML), 30 'u akut limfoblastik lösemi (ALL), 40 '1 akut Non-limfoblastik lösemi (ANLL) olmak üzere toplam 231 olguda serum kolesterol ve 218 olguda serum trigliserid, düzeyleri ölçüldü. KLL 'li 7 (% 22. 5), NHL 'lı 9 (% 22.5), HL 'Iı 7 (% 22.5), KML 'Ii (% 17.9), ALL'li 10 (% 33.3), ANLL'It 15 (% 37.5) olguda serum kolesterol düzeyi normal değerin altında saptandı. KLL 'li 7 (% 28), NHL 'lı ll (% 28), HL lı 51 (% 1 6), KML 'lı 15 (% 40), multiple myeloma t 4 (% 21), ALL 'li 9 (% 30), ANLL 'li 13 (% 33.3) olguda serum trigliserid seviyeleri normalin üzerinde saptandi. Multipl myeloma lı olgularda hiperkolesterolemi saptanmadı.

In this study we investigated the incidance (frequency) of hypercholesterolemia and hypertriglyceridemia in patients with different hematologic malignancies, who have not received any specific treatment, by measuring serum total cholesterol and triglyceride levels. Serum cholesterol !levels were measured in total 2 31 patients who 31 patients had chronic lymphocytic leukaemia (CLL) 40 patients had Non-hodgkin lymphoma (NHL), 31 patients had Hodgkin Lymphoma (HL), 29 patients had Chronic Myelocytic Leukaemia (CML), 30 patients had acute lymphoblastic leukaemia (ALL), 40 patients had acute non lymphoblastic leukaemia (ANLL} and serum triglyceride levels were measured in 218 cases. 7 patients with ALL (22.5 %), 9 patients with NHL (22.5 %), 7 patier.ts with HL (22.5 %), 7 patients with CML (17.9 %), 10 patients with ALL (33. 3 %) had serum cholesterol !eve/s lower than normal values. Serum triglyceride levels were higher then normal value in 7 CLL patients (28 %), I 1 NHL patients (28 %), 51 HL patients (16 %), 15 CML patients (40 %), 4 multiple myeloma patients (21 %), 9 ALL patients (30 %). Hypercho/esterolaemiahas not been found in patients who had multiple myeloma.